Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 311 Other hematologic neoplasm 80 Myeloid 8 Sarcoma 5 Classical hematology 4 Plasma cell 3 Other solid neoplasm 2 CNS 2 Tumor-Agnostic 1 Genitourinary 1

Conditions

Interventions

pembrolizumab 55 Specimen Handling 28 Biopsy 28 Magnetic Resonance Spectroscopy 27 Paclitaxel 23 Blood Specimen Collection 22 Nivolumab 20 atezolizumab 18 Standard of Care 18 Carboplatin 18 Bevacizumab 18 Surveys and Questionnaires 17 Fluorouracil 14 Oxaliplatin 13 Cisplatin 13 Leucovorin 12 Cyclophosphamide 12 Radiotherapy 11 Radiosurgery 11 Pemetrexed 11 Capecitabine 11 Irinotecan 10 Gemcitabine 10 Docetaxel 10 Ipilimumab 9 trastuzumab deruxtecan 8 olaparib 8 durvalumab 8 Taxes 8 Trastuzumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Rituximab × Tumor-Agnostic × 1 year × Clear all

NCT06031233 2026-03-30

MINUTE

Isala

Phase 4 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡